PARP INHIBITOR MARKET ANALYSIS

PARP Inhibitor Market, By Drug Type (Niraparib, Olaparib, Rucaparib, Talazoparib, Veliparib, Others), By Application (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jul 2024
Code : CMI3037
Pages :147
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

PARP Inhibitor Market Regional Insights

To learn more about this report, request sample copy

North America dominates the global PARP inhibitor market with an estimated market share of 40.2% in 2024, due to strong presence of leading pharmaceutical companies in the U.S. and Canada that are actively involved in the research and development of innovative PARP inhibitors. Companies like AstraZeneca, Tesaro, Clovis Oncology and Johnson & Johnson have their headquarters in the region. Furthermore, the availability of favorable reimbursement policies for cancer drugs and growing adoption of precision medicine have supported the uptake of PARP inhibitors in the treatment of cancers like ovarian and breast.

However, Asia Pacific region is poised to be the fastest growing market due to rising burden of cancer, increasing healthcare investments by various governments and expansion strategies adopted by key market players. China, Japan and India represent the most lucrative market opportunities due to their large patient pools. Additionally, new manufacturing facilities set up by global drugmakers to cater to the demand from the Asia's emerging economies have made PARP inhibitors more affordable. This has positively influenced their usage across major hospitals as well as small private clinics.